2018 Press Releases

Neurocrine Biosciences at the Jefferies London Healthcare Conference (Replay)
11/14/18 at 6:20 a.m. ET

Neurocrine Biosciences at the Jefferies London Healthcare Conference
Wednesday, November 14, 2018 6:20 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Keyword Search
 
DateTitle 
11/14/18AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo -Results were consistent across both pivotal Phase 3 studies (ELARIS UF-1 and ELARIS UF-2) - FDA New Drug Application submission anticipated in mid-2019  NORTH CHICAGO, Ill., Nov. 14, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation wit... 
Printer Friendly Version
11/07/18Neurocrine Biosciences to Present at the Jefferies 2018 London Healthcare Conference
Live Audio Webcast will be on November 14, 2018 SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2018 London Healthcare Conference at 11:20 a.m. GMT (6:20 a.m. ET) on Wednesday, Nov. 14, 2018, in London. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference. The live presentation will be webcast and may be accessed on the Company's we... 
Printer Friendly Version
11/05/18Neurocrine Biosciences Reports Third Quarter 2018 Financial Results
INGREZZA® (valbenazine) Third Quarter Net Product Sales of $111.3 Million with Approximately 19,400 TRx Expanded Clinical Development Pipeline - Phase I Studies Initiated with a Novel VMAT2 Inhibitor and a First-in-Class CNS Compound SAN DIEGO, Nov. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2018, and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development pro... 
Printer Friendly Version
10/23/18Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress
New Data Also Examine the Impact of Uncontrollable Movements as Reported by Patients, Caregivers and Healthcare Providers from RE-KINECT, the Largest Real-World Screening Study of Patients with Possible Tardive Dyskinesia SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new data analyses on the long-term effects of INGREZZA® (valbenazine) capsules in adults with tardive dyskinesia (TD) and from RE-KINECT, the largest real-wor... 
Printer Friendly Version
10/15/18Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Monday, November 5 SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants... 
Printer Friendly Version
10/09/18Neurocrine Biosciences and Jnana Therapeutics Enter Strategic Collaboration to Discover Novel Medicines to Treat Central Nervous System Disorders
Partnership Leverages Neurocrine's Expertise in Neuroscience and Jnana's Proprietary Drug Discovery Platform Targeting the Solute Carrier Family of Transporters SAN DIEGO and BOSTON, Oct. 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders. The collaboration will l... 
Printer Friendly Version
10/05/18AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis
Endometriosis affects up to one in 10 women of reproductive age in Canada.1  7 out of 10 women being managed for endometriosis have unresolved pain throughout the month.2 The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women. In clinical trials, ORILISSA™demonstrated sustained relief over 12 months across the two most common types of pain: dysmenorrhea and non-menstrual pelvic pain.3    MONTREAL, Oct. 5, 2018 /CN... 
Printer Friendly Version
10/01/18Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders
New Long-Term Data from Phase III KINECT 4 Study Highlights Efficacy of INGREZZA Across Body Regions in Patients with Tardive Dyskinesia SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new long-term data analyses on INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), at the 2018 International Congress of Parkinson's Disease and Movemen... 
Printer Friendly Version
09/05/18Neurocrine Biosciences to Present at the Morgan Stanley 16th Annual Global Healthcare Conference
Live Audio Webcast will be on September 12, 2018 SAN DIEGO, Sept. 5, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Morgan Stanley 16th Annual Global Healthcare Conference at 8:10 a.m. ET on Wednesday, Sept. 12, 2018, in New York City. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under ... 
Printer Friendly Version
08/22/18AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
- Study results (ELARIS UF-EXTEND) showed elagolix, in combination with add-back therapy, reduced heavy menstrual bleeding for up to 12 months - Results were consistent with two pivotal Phase 3 studies (ELARIS UF-I and ELARIS UF-II) and no new safety signals were identified - Data from the pivotal studies will be presented at a medical conference later this yearNORTH CHICAGO, Ill., Aug. 22, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in coo... 
Printer Friendly Version
08/15/18Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders
New Long-Term Analyses Highlight Patient-Reported Outcomes and Patient Satisfaction with INGREZZA for the Treatment of Tardive Dyskinesia Three Analyses from Phase III Study Demonstrate Opicapone Improves Motor Fluctuations in Patients with Parkinson's Disease SAN DIEGO, Aug. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA® (valbenazine) capsul... 
Printer Friendly Version
07/31/18Neurocrine Biosciences Reports Second Quarter 2018 Financial Results
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx ORILISSA™ (elagolix), the First FDA-Approved Oral Treatment for Moderate to Severe Endometriosis Pain in Over a Decade, Expected to be Launched by AbbVie in August 2018 SAN DIEGO, July 31, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2018, and provided an update on the launch of INGREZZA® (valbenazin... 
Printer Friendly Version
07/24/18AbbVie Receives U.S. FDA Approval of ORILISSA(elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade - ORILISSA is available in two oral dosages-150 mg once daily and 200 mg twice daily, taken with or without food - FDA approval is supported by the largest endometriosis Phase 3 study program conducted to date - ORILISSA is expected to be available in U.S. retail pharmacies in early August 2018 NORTH CHICAGO, Ill., July 24, 2018 /PRNewsw... 
Printer Friendly Version
07/10/18Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Tuesday, July 31 SAN DIEGO, July 10, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Tuesday, July 31, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participa... 
Printer Friendly Version
06/08/18Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego
SAN DIEGO, June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, received the Entrepreneur Of The Year® 2018 Award in the Life Sciences category in San Diego . The EY awards program recognizes entrepreneurs whose ingenuity, spirit of innovation an... 
Printer Friendly Version
05/09/18Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Live Audio Webcast Will be on May 15, 2018 SAN DIEGO, May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 15, 2018, in Las Vegas, Nevada. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine... 
Printer Friendly Version
05/08/18Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
- Nearly 28 Percent of Patients Treated with Antipsychotics in the RE-KINECT Study Had Clinician-Confirmed Possible Tardive Dyskinesia - Over Half of Patients with Possible Tardive Dyskinesia Experienced Uncontrollable Movements in Two or More Body Regions - New Data from KINECT 4 Study Show Long-Term Treatment with INGREZZA® (valbenazine) Capsules Provided Sustained, Clinically Meaningful Improvement in Tardive Dyskinesia and was Well-Tolerated SAN DIEGO, May 8, 2018 /PRNewswire/ -- Ne... 
Printer Friendly Version
05/02/18Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
New Data Provide Insight Into the Real-World Impact of Potential Tardive Dyskinesia in Patients Treated With Antipsychotic Medicines New Data From KINECT 4 Study Describe the Results of Long-Term INGREZZA® (valbenazine) Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NASDAQ: NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date ... 
Printer Friendly Version
04/30/18Neurocrine Biosciences Reports First Quarter 2018 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads to Expansion of Sales Force Increased Investment in Tourette Syndrome Clinical Program with Initiation of T-Force PLATINUM Study Two Positive Phase III Clinical Study Results for Elagolix in Uterine Fibroids, NDA Anticipated in 2019 SAN DIEGO, April 30, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results... 
Printer Friendly Version
04/27/18AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids- Primary and secondary efficacy and safety data to be presented from two extension Phase 3 studies evaluating the use of elagolix in women with endometriosis with associated moderate to severe pain- New productivity data from a Phase 2b study evaluating elagolix in women with uterine fibroids will also be presentedNORTH CHICAGO, Ill., April 27, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a... 
Printer Friendly Version
04/25/18Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
Additional Long-Term Data Show INGREZZA Sustained Improvement of Tardive Dyskinesia Symptoms Through 48 Weeks of Treatment and was Well-Tolerated SAN DIEGO, April 25, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), improved TD symptoms regardless of body region. These new data analyses, along with long-... 
Printer Friendly Version
04/23/18Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Monday, April 30 SAN DIEGO, April 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 30, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Participants can access the live conference... 
Printer Friendly Version
04/18/18Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
New Data Evaluating Efficacy of INGREZZA Across Body Regions in Patients with Tardive Dyskinesia Data from KINECT 4 Study Demonstrate Long-Term Efficacy and Tolerability in Patients with Tardive Dyskinesia SAN DIEGO, April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), will be prese... 
Printer Friendly Version
04/10/18AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
- FDA requires extended time for review of additional information in New Drug Application (NDA) - Elagolix clinical trial program largest prospective randomized endometriosis trial conducted to date - Based on AbbVie's review of the data, the company remains confident in NDA and continues to work with FDA to bring elagolix to patients - Regulatory submissions for elagolix in uterine fibroids remain on track NORTH CHICAGO, Ill., April 10, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global r... 
Printer Friendly Version
03/13/18AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
- Second of two pivotal Phase 3 studies (ELARIS UF-II) met primary efficacy endpoint and all ranked secondary endpoints - Results were consistent with the first Phase 3 study (ELARIS UF-I) and demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual bleeding compared to placebo - Data will be presented at an upcoming medical conference NORTH CHICAGO, Ill., March 13, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopha... 
Printer Friendly Version
03/07/18Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO, March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman, CEO of Neurocrine Biosciences, will present at the following investor conferences: Cowen and Company 38th Annual Health Care Conference at 10:00 a.m. ET on Wednesday, March 14, 2018, in Boston. Barclays Global Healthcare Conference at 1:35 p.m. ET on Thursday, March 15, 2018, in Miami. Oppenheimer 28th Annual Healthcare Conference at 10:55 a.m. ET on Wednesda... 
Printer Friendly Version
02/21/18AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
- First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints - Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual bleeding compared to placebo - Data will be presented at an upcoming medical conference NORTH CHICAGO, Ill., Feb. 21, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine... 
Printer Friendly Version
02/14/18Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
Neurocrine Plans to File the NDA During the First Half of 2019 SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the regulatory path forward to support the New Drug Application (NDA) for opicapone, an investigational drug for Parkinson's disease, after receiving meeting minutes from the Ja... 
Printer Friendly Version
02/13/18Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch on May 1, 2017 Total Revenue for the Fourth Quarter of 2017 was $94.5 Million and $161.6 Million for the Full-Year 2017 Elagolix PDUFA Action Date for Endometriosis in Q2 2018 and Uterine Fibroids Data from Two Phase III Studies Expected in Q1 2018 Results from Phase IIb Study of Valbe... 
Printer Friendly Version
02/08/18Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Live Audio Webcast Will be on February 15, 2018 SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7th Annual Global Healthcare Conference at 11:30 a.m. ET on Thursday, Feb. 15, 2018, in New York City. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com. A replay of the ... 
Printer Friendly Version
02/06/18Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results
Conference Call and Webcast Scheduled for Tuesday, February 13 SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq market closes on Tuesday, Feb. 13, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Participants can acces... 
Printer Friendly Version
01/07/18Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer
SAN DIEGO, Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Christopher O'Brien, M.D., Chief Medical Officer, has notified the Company he plans to retire in February 2018, after a transition period with his successor. Dr. O'Brien joined Neurocrine in 2005, and has led the clinical development and medical affairs activities for more than 12 years. Dr. O'Brien will remain ... 
Printer Friendly Version
01/07/18Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017 - INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $64 Million with Approximately 9,100 TRx - Received $30 Million Milestone from AbbVie for the Elagolix Endometriosis NDA Acceptance During the Fourth Quarter of 2017 - INGREZZA® (valbenazine) Preliminary Net Product Sales of Approximately $116 Million with Approximately 14,... 
Printer Friendly Version
01/02/18Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast Will be on January 8, 2018 SAN DIEGO, Jan. 2, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, Jan. 8, 2018, in San Francisco. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A replay of the presentation will ... 
Printer Friendly Version